[go: up one dir, main page]

TR201905814T4 - Jak inhibitörü olarak bipirazol tuzu. - Google Patents

Jak inhibitörü olarak bipirazol tuzu.

Info

Publication number
TR201905814T4
TR201905814T4 TR2019/05814T TR201905814T TR201905814T4 TR 201905814 T4 TR201905814 T4 TR 201905814T4 TR 2019/05814 T TR2019/05814 T TR 2019/05814T TR 201905814 T TR201905814 T TR 201905814T TR 201905814 T4 TR201905814 T4 TR 201905814T4
Authority
TR
Turkey
Prior art keywords
biprazole
jack
inhibitor
salt
jak
Prior art date
Application number
TR2019/05814T
Other languages
English (en)
Inventor
Li Yun-Long
Zhuo Jincong
Qian Ding-Quan
Mei Song
Cao Ganfeng
Pan Yongchun
Li Qun
Jia Zhongjiang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of TR201905814T4 publication Critical patent/TR201905814T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Mevcut buluş, Formül I: Bileşimi veya bunun farmasötik olarak kabul edilebilir tuzlarının yanı sıra, Janus kinaz (JAK) aktivitesini inhibe eden ve örneğin inflamatuar bozukluklar, otoimmün bozukluklar, kanser ve başka hastalıkları kapsayan, JAK aktivitesiyle ilgili hastalıkların tedavisinde faydalı olan bipirazol türevlerinin yanı sıra bunların bileşimleri ve kullanım metotlarını sağlamaktadır.
TR2019/05814T 2013-05-17 2014-05-16 Jak inhibitörü olarak bipirazol tuzu. TR201905814T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361824683P 2013-05-17 2013-05-17

Publications (1)

Publication Number Publication Date
TR201905814T4 true TR201905814T4 (tr) 2019-05-21

Family

ID=50983151

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05814T TR201905814T4 (tr) 2013-05-17 2014-05-16 Jak inhibitörü olarak bipirazol tuzu.

Country Status (36)

Country Link
US (8) US9382231B2 (tr)
EP (6) EP3786162B1 (tr)
JP (5) JP6415543B2 (tr)
KR (4) KR102663357B1 (tr)
CN (2) CN105452239B (tr)
AR (2) AR096330A1 (tr)
AU (5) AU2014265279B2 (tr)
BR (1) BR112015028501B8 (tr)
CA (1) CA2911536C (tr)
CL (1) CL2015003355A1 (tr)
CR (2) CR20190156A (tr)
CY (3) CY1119105T1 (tr)
DK (4) DK3786162T3 (tr)
EA (2) EA036448B1 (tr)
ES (5) ES2960731T3 (tr)
FI (2) FI4275756T3 (tr)
HK (1) HK1245769B (tr)
HR (5) HRP20231048T1 (tr)
HU (4) HUE043573T2 (tr)
IL (4) IL242453B (tr)
LT (5) LT2997023T (tr)
ME (2) ME03355B (tr)
MX (2) MX373238B (tr)
MY (1) MY174788A (tr)
PE (2) PE20160126A1 (tr)
PH (2) PH12015502563B1 (tr)
PL (4) PL2997023T3 (tr)
PT (5) PT3527263T (tr)
RS (5) RS58743B1 (tr)
SG (2) SG11201509180WA (tr)
SI (5) SI3527263T1 (tr)
SM (5) SMT202300352T1 (tr)
TR (1) TR201905814T4 (tr)
TW (4) TWI885650B (tr)
UA (1) UA117830C2 (tr)
WO (1) WO2014186706A1 (tr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3184526T1 (sl) 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
MX2009013402A (es) 2007-06-13 2010-02-24 Incyte Corp Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
PT2448938E (pt) 2009-06-29 2014-07-31 Incyte Corp Pirimidinonas como inibidoras de pi3k
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
BR112013012502A2 (pt) 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
EP2721028B1 (en) 2011-06-20 2015-11-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
EP3196202B1 (en) 2011-09-02 2019-02-27 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
WO2014071031A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
FI4275756T3 (fi) 2013-05-17 2025-10-20 Incyte Holdings Corp Bipyratsolin johdannaisia jak-estäjinä
LT3030227T (lt) 2013-08-07 2020-06-10 Incyte Corporation Prailginto atpalaidavimo jak1 inhibitoriaus dozavimo formos
SI3110409T1 (sl) * 2014-02-28 2018-11-30 Incyte Corporation Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov
WO2015157257A1 (en) 2014-04-08 2015-10-15 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
SG10201809518QA (en) 2014-04-30 2018-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
PL3262046T3 (pl) 2015-02-27 2021-05-04 Incyte Corporation Sole inhibitora pi3k i sposoby ich wytwarzania
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
CN118453493A (zh) 2015-05-29 2024-08-09 西德奈克西斯公司 D2o稳定化的药物制剂
LT3371190T (lt) 2015-11-06 2022-08-10 Incyte Corporation Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
AR107293A1 (es) 2016-01-05 2018-04-18 Incyte Corp COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
CA3035712A1 (en) * 2016-09-06 2018-03-15 F. Hoffmann-La Roche Ag 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
MX2020007973A (es) 2018-01-30 2020-12-07 Incyte Corp Procesos para preparar (1-(3-fluoro-2-(trifluorometil)isonicotinil )piperidin-4-ona).
KR20240157777A (ko) * 2018-02-16 2024-11-01 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
SI3773593T1 (sl) * 2018-03-30 2024-08-30 Incyte Corporation Zdravljenje hidradenitisa suppurative z zaviralci jak
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
MA52208A (fr) * 2018-04-13 2021-02-17 Incyte Corp Biomarqueurs pour une maladie du greffon contre l'hôte
CN108484468A (zh) * 2018-05-11 2018-09-04 南京大学 芳基氮杂环丁烷类化合物的制备方法
KR102884803B1 (ko) 2018-06-01 2025-11-12 인사이트 코포레이션 Pi3k 관련 장애의 치료를 위한 투여 요법
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
EA202191170A1 (ru) 2018-10-31 2021-07-27 Инсайт Корпорейшн Комбинированная терапия для лечения гематологических заболеваний
PH12021551455A1 (en) 2018-12-19 2022-04-18 Incyte Corp Jak1 pathway inhibitors for the treatment of gastrointestinal disease
PH12021552130A1 (en) 2019-03-05 2022-08-31 Incyte Corp Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021062163A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US12203942B2 (en) 2019-10-10 2025-01-21 Incyte Corporation Biomarkers for graft-versus-host disease
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
PT4157831T (pt) 2020-06-02 2024-12-20 Incyte Corp Processos de preparação de um inibidor de jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4200300A1 (en) 2020-08-18 2023-06-28 Incyte Corporation Process and intermediates for preparing a jak inhibitor
AR123268A1 (es) 2020-08-18 2022-11-16 Incyte Corp Proceso e intermediarios para preparar un inhibidor de jak1
CN112159394B (zh) * 2020-10-09 2021-10-22 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
US12005067B2 (en) 2020-12-04 2024-06-11 Incyte Corporation JAK inhibitor with a vitamin D analog for treatment of skin diseases
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN114081889A (zh) * 2020-12-29 2022-02-25 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
WO2022150676A1 (en) 2021-01-11 2022-07-14 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
TW202308610A (zh) 2021-05-03 2023-03-01 美商英塞特公司 用於治療結節性癢疹之ｊａｋ１途徑抑制劑
EP4370504A1 (en) 2021-07-12 2024-05-22 Incyte Corporation Process and intermediates for preparing baricitinib
JP2025527297A (ja) 2022-08-05 2025-08-20 インサイト・コーポレイション Ｊａｋ阻害剤を使用した蕁麻疹の処置
AU2024236890A1 (en) 2023-03-16 2025-09-25 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma
CN117186078A (zh) * 2023-11-06 2023-12-08 药康众拓(北京)医药科技有限公司 氘代氮杂环丁烷类jak抑制剂药物及用途
WO2025226637A1 (en) 2024-04-22 2025-10-30 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60106847U (ja) 1983-12-27 1985-07-20 富士重工業株式会社 室外後写鏡
JP2650681B2 (ja) 1987-07-10 1997-09-03 株式会社ブリヂストン 空気ばね
JPH0515775Y2 (tr) 1987-07-13 1993-04-26
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2339961C (en) 1998-08-11 2009-01-20 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
NZ522783A (en) 2000-06-28 2004-07-30 Smithkline Beecham P Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant
EA007983B1 (ru) 2001-09-19 2007-02-27 Авентис Фарма С.А. Индолизины в качестве ингибиторов киназных белков
KR100926194B1 (ko) 2001-10-30 2009-11-09 노파르티스 아게 Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의스타우로스포린 유도체
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
MX2007006204A (es) 2004-11-24 2007-06-20 Novartis Ag Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
SI3184526T1 (sl) 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MX2009013402A (es) 2007-06-13 2010-02-24 Incyte Corp Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
US8309718B2 (en) * 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
CN102026999B (zh) * 2008-03-11 2014-03-05 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX2012004180A (es) 2009-10-09 2012-07-17 Incyte Corp Derivados de hidroxil, ceto y glucuronido de 3-(4-7h-pirrolo[2,3-d ]pirimidin-a-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo.
AU2011217961B2 (en) 2010-02-18 2016-05-05 Incyte Holdings Corporation Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
WO2011130146A1 (en) * 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
BR112013012502A2 (pt) 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
US9926601B2 (en) 2011-02-24 2018-03-27 Massachusetts Institute Of Technology Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer
EP2721028B1 (en) * 2011-06-20 2015-11-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AU2012312303B2 (en) 2011-09-22 2016-09-15 Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides as janus kinase inhibitors
AR091079A1 (es) * 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
WO2014071031A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
FI4275756T3 (fi) * 2013-05-17 2025-10-20 Incyte Holdings Corp Bipyratsolin johdannaisia jak-estäjinä
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
BR112015028873A2 (pt) 2013-05-17 2017-07-25 Hoffmann La Roche heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
LT3030227T (lt) 2013-08-07 2020-06-10 Incyte Corporation Prailginto atpalaidavimo jak1 inhibitoriaus dozavimo formos
SI3110409T1 (sl) 2014-02-28 2018-11-30 Incyte Corporation Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov
SG10201809518QA (en) 2014-04-30 2018-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
SI3233843T1 (sl) 2014-12-16 2019-12-31 Novartis Ag Spojine izoksazol hidroksamične kisline kot LPXC inhibitorji
KR20240157777A (ko) 2018-02-16 2024-11-01 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
PT4157831T (pt) 2020-06-02 2024-12-20 Incyte Corp Processos de preparação de um inibidor de jak1
US12005067B2 (en) 2020-12-04 2024-06-11 Incyte Corporation JAK inhibitor with a vitamin D analog for treatment of skin diseases
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo

Also Published As

Publication number Publication date
RS61482B1 (sr) 2021-03-31
CN105452239B (zh) 2017-11-21
SI3527263T1 (sl) 2021-05-31
AR118120A2 (es) 2021-09-22
AU2020202000A1 (en) 2020-04-09
EP4620528A2 (en) 2025-09-24
IL282644B (en) 2021-10-31
RS58743B1 (sr) 2019-06-28
HRP20251220T1 (hr) 2025-12-05
CY1119105T1 (el) 2018-02-14
CL2015003355A1 (es) 2016-05-27
US11905275B2 (en) 2024-02-20
KR20210120120A (ko) 2021-10-06
UA117830C2 (uk) 2018-10-10
PT3786162T (pt) 2023-10-20
US20200010456A1 (en) 2020-01-09
SI3231801T1 (sl) 2019-05-31
EP3231801B1 (en) 2019-02-13
AU2018223058A1 (en) 2018-09-20
HK1245769B (en) 2020-02-07
PL2997023T3 (pl) 2017-08-31
MX2020004506A (es) 2021-08-09
TW202432140A (zh) 2024-08-16
US20210238168A1 (en) 2021-08-05
SMT202500397T1 (it) 2025-11-10
LT3786162T (lt) 2023-11-27
PL3231801T3 (pl) 2019-07-31
TW201512191A (zh) 2015-04-01
ME03355B (me) 2019-10-20
EP3231801A1 (en) 2017-10-18
EP3786162A1 (en) 2021-03-03
EA039660B1 (ru) 2022-02-24
CY1121763T1 (el) 2020-07-31
WO2014186706A1 (en) 2014-11-20
TWI719401B (zh) 2021-02-21
IL264409B (en) 2021-05-31
PT2997023T (pt) 2017-05-31
FI3786162T3 (fi) 2023-10-02
EA202090291A3 (ru) 2020-06-30
US20160289215A1 (en) 2016-10-06
JP2021008493A (ja) 2021-01-28
HUE033587T2 (hu) 2017-12-28
PH12018502125A1 (en) 2019-03-25
ME02763B (me) 2018-01-20
NZ713999A (en) 2020-11-27
AU2022263454B2 (en) 2024-01-18
LT3527263T (lt) 2021-05-10
AU2022263454A1 (en) 2022-12-08
LT2997023T (lt) 2017-06-26
KR102341908B1 (ko) 2021-12-23
AU2014265279B2 (en) 2018-09-27
LT3231801T (lt) 2019-08-12
US9382231B2 (en) 2016-07-05
IL287313A (en) 2021-12-01
MX373238B (es) 2020-05-08
SG10201709469SA (en) 2017-12-28
NZ753636A (en) 2020-11-27
RS56012B1 (sr) 2017-09-29
SG11201509180WA (en) 2015-12-30
LT4275756T (lt) 2025-11-10
US20240150327A1 (en) 2024-05-09
TW202116320A (zh) 2021-05-01
KR102663357B1 (ko) 2024-05-14
EA201592199A1 (ru) 2016-05-31
KR20240063187A (ko) 2024-05-10
JP7126741B2 (ja) 2022-08-29
PH12015502563B1 (en) 2019-04-26
JP2024105557A (ja) 2024-08-06
US20250206726A1 (en) 2025-06-26
US10435392B2 (en) 2019-10-08
NZ753639A (en) 2020-11-27
IL287313B (en) 2022-03-01
EP2997023A1 (en) 2016-03-23
ES2960731T3 (es) 2024-03-06
HRP20210119T1 (hr) 2021-03-05
ES3047826T3 (en) 2025-12-05
HRP20231048T1 (hr) 2023-12-22
EA036448B1 (ru) 2020-11-11
CA2911536A1 (en) 2014-11-20
RS67392B1 (sr) 2025-11-28
PT3527263T (pt) 2021-02-01
PT4275756T (pt) 2025-10-31
JP2016519147A (ja) 2016-06-30
EP3786162B1 (en) 2023-08-09
DK3231801T3 (en) 2019-04-15
TWI885650B (zh) 2025-06-01
PT3231801T (pt) 2019-05-24
ES2626793T3 (es) 2017-07-26
ES2720073T3 (es) 2019-07-17
JP2019011364A (ja) 2019-01-24
NZ753637A (en) 2020-11-27
CR20190156A (es) 2019-05-16
SMT201700258T1 (it) 2017-07-18
IL242453B (en) 2019-11-28
HRP20190713T1 (hr) 2019-06-14
JP6415543B2 (ja) 2018-10-31
MY174788A (en) 2020-05-14
US20230159501A1 (en) 2023-05-25
BR112015028501B1 (pt) 2022-11-01
US9926301B2 (en) 2018-03-27
DK3527263T3 (da) 2021-01-25
KR102729910B1 (ko) 2024-11-15
AU2018223058B2 (en) 2020-01-02
EP2997023B1 (en) 2017-03-22
HUE043573T2 (hu) 2019-08-28
HK1221466A1 (en) 2017-06-02
CY1123756T1 (el) 2022-05-27
CN107698569A (zh) 2018-02-16
AU2014265279A1 (en) 2015-11-26
BR112015028501B8 (pt) 2023-01-24
HUE053122T2 (hu) 2021-06-28
BR112015028501A2 (pt) 2017-07-25
EP4275756A2 (en) 2023-11-15
CA2911536C (en) 2021-07-20
SMT201900223T1 (it) 2019-07-11
DK4275756T3 (da) 2025-09-29
HUE063817T2 (hu) 2024-01-28
JP6775560B2 (ja) 2020-10-28
EP4275756A3 (en) 2024-02-07
CN105452239A (zh) 2016-03-30
TWI664176B (zh) 2019-07-01
SMT202300352T1 (it) 2024-01-10
SI4275756T1 (sl) 2025-12-31
SMT202100040T1 (it) 2021-03-15
JP2022163162A (ja) 2022-10-25
EP4620528A3 (en) 2025-11-26
KR20160019905A (ko) 2016-02-22
EP2997023B9 (en) 2018-06-13
PL3527263T3 (pl) 2021-05-17
RS64591B1 (sr) 2023-10-31
MX2015015738A (es) 2016-03-16
MX385187B (es) 2025-03-14
HRP20170795T1 (hr) 2017-08-25
AU2020202000B2 (en) 2021-03-11
US20180312492A1 (en) 2018-11-01
KR20220127371A (ko) 2022-09-19
CN107698569B (zh) 2020-11-27
CR20150633A (es) 2016-04-05
EA202090291A2 (ru) 2020-05-31
PL3786162T3 (pl) 2024-04-08
SI2997023T1 (sl) 2017-07-31
TW201940479A (zh) 2019-10-16
KR102442747B1 (ko) 2022-09-14
ES2845210T3 (es) 2021-07-26
PE20160126A1 (es) 2016-02-24
AU2021202685A1 (en) 2021-05-27
US11591318B2 (en) 2023-02-28
EP4275756B1 (en) 2025-09-03
US11001571B2 (en) 2021-05-11
PH12015502563A1 (en) 2016-02-22
NZ753638A (en) 2020-11-27
US20140343030A1 (en) 2014-11-20
PE20200527A1 (es) 2020-03-09
TWI840646B (zh) 2024-05-01
AU2021202685B2 (en) 2022-11-17
FI4275756T3 (fi) 2025-10-20
EP3527263B1 (en) 2020-10-28
EP3527263A1 (en) 2019-08-21
AR096330A1 (es) 2015-12-23
SI3786162T1 (sl) 2024-02-29
IL282644A (en) 2021-06-30
DK3786162T3 (da) 2023-10-09
US12247020B2 (en) 2025-03-11
IL264409A (en) 2019-02-28

Similar Documents

Publication Publication Date Title
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MD4666B1 (ro) Inhibitori ai Syk
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201690094A1 (ru) Ингибиторы syk
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
TR201816379T4 (tr) DNA-PK inhibitörleri.
EA201690752A1 (ru) Ингибиторы g12c kras
EA201990833A1 (ru) Соединение пиридина
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201591628A1 (ru) Дейтерированный палбоциклиб
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.
MY192305A (en) Bipyrazole derivatives as jak inhibitors
UA110978C2 (uk) Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak